Latest News - AMD

Thursday, February 22, 2018

Apellis Pharmaceuticals Announces 18-Month Results of Phase 2 Study (FILLY) of APL-2 in Geographic Atrophy

Apellis Pharmaceuticals will provide an update with 18-month data on its phase 2 trial (FILLY) of its complement C3 inhibitor, APL-2, in patients with geographic atrophy (GA) associated with age-relat…

Read the full story

Monday, February 12, 2018

Phase 2 Data Support Potential for Novel Anti-VEGF/Anti-Angiopoietin-2 Bispecific Antibody, RG7716, for People with DME

Genentech announced encouraging results from the phase 2 BOULEVARD study. In people with vision loss from diabetic macular edema (DME), treatment with intravitreal RG7716 demonstrated clinically meani…

Read the full story

Tuesday, February 06, 2018

Bausch + Lomb and Prevent Blindness Encourage People to Fight for Their Sight During February and AMD Awareness Month

Bausch + Lomb announced the launch of a public service announcement and docu-series designed to raise awareness of age-related macular degeneration (AMD). The series includes deeply powerful stories o…

Read the full story

Tuesday, January 30, 2018

Eyepromise Introduces New Formula of Eyepromise Restore for Patients with Early Signs of AMD

EyePromise announced the introduction of a new and improved formula to its EyePromise Restore line, with the addition of vitamins B6 and B12, folic acid, and Coenzyme Q10 (CoQ10), according to a …

Read the full story

Thursday, January 25, 2018

Pixium Vision Completes World’s First Successful Activation in Human of PRIMA Bionic Vision System

Pixium Vision announced the first successful human implantation and activation of PRIMA, its new generation miniaturized wireless photovoltaic subretinal implant, in a patient with severe vision loss …

Read the full story

Friday, January 05, 2018

Ohr Pharmaceutical Misses Primary Efficacy Endpoint in Wet-AMD Study

Ohr Pharmaceutical reported topline data from the MAKO study, which did not meet its primary efficacy endpoint. The MAKO study evaluated the efficacy and safety of topically administered squalamine in…

Read the full story

Wednesday, November 08, 2017

LumiThera Unveils LIGHTSITE 1 Dry AMD Clinical Interim Data

LumiThera announced topline interim results from the LIGHTSITE 1 trial for treatment of dry age-related macular degeneration (AMD) trial utilizing its LT-300 device. The 30-subject pilot study funded …

Read the full story

Thursday, October 19, 2017

Genentech Completes Patient Enrollment In Phase 2 Study Evaluating A New Delivery System for Lucentis

Genentech has completed enrollment in the LADDER (Long Acting Delivery of Ranibizumab) trial, a phase 2, multicenter, randomized, active treatment-controlled clinical trial investigatin…

Read the full story

Thursday, October 19, 2017

Pixium Vision Receives Approval for First-in-Human Clinical Trial of PRIMA, Its Miniaturized Sub-Retinal Implant

Pixium Vision announced that its next-generation miniaturized wireless subretinal implant, PRIMA, aimed at restoring vision in patients affected by retinal dystrophies, received authorization from the…

Read the full story

Friday, October 06, 2017

PanOptica Secures Funding to Advance Clinical Development of PAN-9080 Topical Anti-VEGF Eye Drop

PanOptica announced that it has secured $11 million in a Series B financing to enable clinical advancement of PAN-90806, a small molecule anti-vascular endothelial growth factor (anti-VEGF) eye drop f…

Read the full story

Thursday, October 05, 2017

Aerie Pharmaceuticals Announces Drug Delivery Asset Acquisition to Advance Its Retinal Disease Program

Aerie Pharmaceuticals announced that it has acquired rights to use Envisia Therapeutics' PRINT technology in ophthalmology and certain other assets. The PRINT technology is a proprietary system ca…

Read the full story

Tuesday, September 19, 2017

Graybug Vision Initiates Phase 1/2 Trial of GB-102 for Wet AMD

Graybug Vision announced that it has begun dosing patients with wet AMD in its first clinical trial of GB-102, its lead product. GB-102 is a novel intravitreal (IVT) injectable depot formulation of su…

Read the full story

Monday, September 11, 2017

Genentech's Lampalizumab Fails Phase 3 Study for Geographic Atrophy

Genentech announced that the primary endpoint has not been met in Spectri, the first of two phase 3 studies evaluating the safety and efficacy of lampalizumab, an investigational medicine for the trea…

Read the full story

Thursday, August 24, 2017

Apellis Pharmaceuticals Announces APL-2 Met its Primary Endpoint in a Phase 2 Study in Patients with Geographic Atrophy

Apellis Pharmaceuticals announced that its complement C3 inhibitor, APL-2, met its primary endpoint in a phase 2 clinical trial (FILLY) in patients with geographic atrophy (GA) associated with age-rel…

Read the full story

Wednesday, August 16, 2017

New Anti-VEGF Drug Promising for Wet Macular Degeneration

A new antivascular endothelial growth-factor (VEGF) drug, OPT-302 (Opthea), appears to be safe and shows signs of effectiveness in the treatment of neovascular age-related macular degeneration, new re…

Read the full story
Load More